Mohammad Saad Salim Naviwala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohammad Saad Salim Naviwala has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Waqas Ahmed Khan
Section of Medical Oncology, Department of Oncology, Aga Khan University Hospital, Karachi, Pakistan.
3 shared publications - Adeeba Zaki
Department of Oncology, The Aga Khan University Hospital
2 shared publications - Yasmin Abdul Rashid
Section of Medical Oncology, Department of Oncology, Aga Khan University Hospital, Karachi, Pakistan
2 shared publications Daania Shoaib
Aga Khan Univ Hosp, Dept Med Oncol, Karachi 74800, Pakistan
1 shared publication- Daania Shoaib
Department of Medical Oncology, The Aga Khan University , National Stadium Road, Karachi 74800
1 shared publication - Daania Shoaib
Department of Medical Oncology, Aga Khan University Hospital, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 28 March 2025
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2025 (4) , omaf009
Metastatic non-small cell lung cancer with BRCA2 mutation—a therapeutic challenge
Non-small cell lung cancer, specifically adenocarcinoma, is amenable to targeted therapy for genetic alterations. The role of BRCA mutations in pathogenesis and the efficacy of PARP inhibitors in these cases are still unclear. This case involves a 61-year-old male patient with a past history of Hodgkin’s Lymphoma and a heavy smoking history who developed lung adenocarcinoma and was found to have a BRCA2 mutation. Following disease progression on first-line chemotherapy and a detailed case discussion in the multidisciplinary team meeting, second-line Olaparib was started, but the patient's condition worsened rapidly, and he died from the illness. This case highlights the fact that BRCA mutations, though less common, are a potential target that should be explored further. Further large-scale studies are crucial to understanding and improving treatment outcomes for patients with BRCA-mutated NSCLC.
- 28 March 2025
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2025 (4) , omaf009
Open AccessMetastatic non-small cell lung cancer with BRCA2 mutation—a therapeutic challenge
Non-small cell lung cancer, specifically adenocarcinoma, is amenable to targeted therapy for genetic alterations. The role of BRCA mutations in pathogenesis and the efficacy of PARP inhibitors in these cases are still unclear. This case involves a 61-year-old male patient with a past history of Hodgkin’s Lymphoma and a heavy smoking history who developed lung adenocarcinoma and was found to have a BRCA2 mutation. Following disease progression on first-line chemotherapy and a detailed case discussion in the multidisciplinary team meeting, second-line Olaparib was started, but the patient's condition worsened rapidly, and he died from the illness. This case highlights the fact that BRCA mutations, though less common, are a potential target that should be explored further. Further large-scale studies are crucial to understanding and improving treatment outcomes for patients with BRCA-mutated NSCLC.
- Open Access
- 27 December 2024
- Published by Jaypee Brothers Medical Publishing in Euroasian Journal of Hepato-Gastroenterology
- Vol. 14 (2) , 246-250
Complete Response with Immunotherapy Alone after Discontinuing VEGF Inhibitor in Advanced Hepatocellular Carcinoma: A Case Report
Naviwala MSS, Shoaib D, Khan WA, et al. Complete Response with Immunotherapy Alone after Discontinuing VEGF Inhibitor in Advanced Hepatocellular Carcinoma: A Case Report. Euroasian J Hepato-Gastroenterol 2024;14(2):246–250.
- 27 December 2024
- Published by Jaypee Brothers Medical Publishing in Euroasian Journal of Hepato-Gastroenterology
- Vol. 14 (2) , 246-250
Open AccessComplete Response with Immunotherapy Alone after Discontinuing VEGF Inhibitor in Advanced Hepatocellular Carcinoma: A Case Report
Naviwala MSS, Shoaib D, Khan WA, et al. Complete Response with Immunotherapy Alone after Discontinuing VEGF Inhibitor in Advanced Hepatocellular Carcinoma: A Case Report. Euroasian J Hepato-Gastroenterol 2024;14(2):246–250.
- Open Access
- 27 December 2024
- Published by Jaypee Brothers Medical Publishing in Euroasian Journal of Hepato-Gastroenterology
- Vol. 14 (2) , 251-257
Overall Survival and the Impact of Albumin-bilirubin Grade in Patients with Advanced Hepatocellular Carcinoma: Data from a Tertiary Care Hospital in a Lower-middle-income Country
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Most patients are diagnosed at an advanced stage, limiting their treatment options. The traditional assessment of liver function using the Child–Pugh score has limitations due to its subjectivity. The albumin-bilirubin (ALBI) grade delivers a more precise evaluation of liver function. This study examines overall survival (OS) in advanced HCC patients treated with first-line systemic therapy and the impact of ALBI grading on these outcomes. A total of 104 patients with advanced HCC treated between January 2017 and December 2023 with one of the three first-line therapy options: Sorafenib, lenvatinib or atezolizumab/bevacizumab were retrospectively analyzed. The Kaplan–Meier method was utilized to examine the survival results, and the log-rank test was employed to evaluate the variations in survival among ALBI grades and therapy types. Cox proportional hazards regression examined the impact of ALBI grading and other covariates on OS, with a significance threshold of p < 0.05 for the multivariable model. The median age of HCC patients was 58.5 years, with 70% males, and a primary etiology of hepatitis C (43%). The median OS and time to progression (TTP) in this cohort were 9 months and 3.25 months. In ALBI grade I patients, the OS was 21 months, while in grade II or III patients, it was just 5 months. Treatment-related side effects necessitated dose reductions in over 84% of patients. Albumin-bilirubin grade, Child–Pugh class, and treatment modifications due to adverse effects were significant predictors of survival. Lenvatinib appears to have better survival outcomes compared to other options. The albumin-bilirubin grading is a useful method for evaluating liver function and forecasting survival rates for individuals with HCC. Our findings support the use of ALBI grading in clinical decision-making for advanced HCC. Naviwala MSS, Tariq M, Ahmed F, et al. Overall Survival and the Impact of Albumin-bilirubin Grade in Patients with Advanced Hepatocellular Carcinoma: Data from a Tertiary Care Hospital in a Lower-middle-income Country. Euroasian J Hepato-Gastroenterol 2024;14(2):251–257.
- 27 December 2024
- Published by Jaypee Brothers Medical Publishing in Euroasian Journal of Hepato-Gastroenterology
- Vol. 14 (2) , 251-257
Open AccessOverall Survival and the Impact of Albumin-bilirubin Grade in Patients with Advanced Hepatocellular Carcinoma: Data from a Tertiary Care Hospital in a Lower-middle-income Country
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Most patients are diagnosed at an advanced stage, limiting their treatment options. The traditional assessment of liver function using the Child–Pugh score has limitations due to its subjectivity. The albumin-bilirubin (ALBI) grade delivers a more precise evaluation of liver function. This study examines overall survival (OS) in advanced HCC patients treated with first-line systemic therapy and the impact of ALBI grading on these outcomes. A total of 104 patients with advanced HCC treated between January 2017 and December 2023 with one of the three first-line therapy options: Sorafenib, lenvatinib or atezolizumab/bevacizumab were retrospectively analyzed. The Kaplan–Meier method was utilized to examine the survival results, and the log-rank test was employed to evaluate the variations in survival among ALBI grades and therapy types. Cox proportional hazards regression examined the impact of ALBI grading and other covariates on OS, with a significance threshold of p < 0.05 for the multivariable model. The median age of HCC patients was 58.5 years, with 70% males, and a primary etiology of hepatitis C (43%). The median OS and time to progression (TTP) in this cohort were 9 months and 3.25 months. In ALBI grade I patients, the OS was 21 months, while in grade II or III patients, it was just 5 months. Treatment-related side effects necessitated dose reductions in over 84% of patients. Albumin-bilirubin grade, Child–Pugh class, and treatment modifications due to adverse effects were significant predictors of survival. Lenvatinib appears to have better survival outcomes compared to other options. The albumin-bilirubin grading is a useful method for evaluating liver function and forecasting survival rates for individuals with HCC. Our findings support the use of ALBI grading in clinical decision-making for advanced HCC. Naviwala MSS, Tariq M, Ahmed F, et al. Overall Survival and the Impact of Albumin-bilirubin Grade in Patients with Advanced Hepatocellular Carcinoma: Data from a Tertiary Care Hospital in a Lower-middle-income Country. Euroasian J Hepato-Gastroenterol 2024;14(2):251–257.
- Open Access
- 16 July 2024
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 18
Esophageal squamous cell carcinoma in a patient with BRCA1 mutation: a rare association
Esophageal squamous cell carcinoma in a patient with BRCA1 mutation: a rare association Mohammad Saad Salim Naviwala1, Mirza Rameez Samar1, Daania Shoaib1,
- 16 July 2024
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 18
Open AccessEsophageal squamous cell carcinoma in a patient with BRCA1 mutation: a rare association
Esophageal squamous cell carcinoma in a patient with BRCA1 mutation: a rare association Mohammad Saad Salim Naviwala1, Mirza Rameez Samar1, Daania Shoaib1,
- Open Access
- 25 January 2024
- Published by Springer Nature in Research Square
Recurrent Cutaneous Manifestation in Multiple Myeloma: A Case Report and Management Approach
Background Cutaneous involvement in multiple myeloma (MM) is an uncommonly encountered manifestation, more commonly observed in patients with aggressive subtypes, and often resistant to conventional therapies. Owing to its infrequency, reported clinical characteristics have been diverse and relatively nonspecific. Particularly uncommon is lower extremity involvement, where cutaneous MM is found. Case presentation In this report, we present a unique case of a middle age lady with refractory IgG lambda MM, who subsequently developed recurrent cutaneous plasmacytoma in the lower leg, while being on systemic therapy. Initially, the lesion resembled squamous cell carcinoma, posing a diagnostic challenge. Through meticulous histopathological and immunohistochemical studies, cutaneous involvement by multiple myeloma was conclusively confirmed. Conclusion This case highlights the importance of maintaining a high clinical suspicion for cutaneous MM in patients with MM who present with new skin lesions, as early diagnosis is crucial for appropriate management.
- 25 January 2024
- Published by Springer Nature in Research Square
Open AccessRecurrent Cutaneous Manifestation in Multiple Myeloma: A Case Report and Management Approach
Background Cutaneous involvement in multiple myeloma (MM) is an uncommonly encountered manifestation, more commonly observed in patients with aggressive subtypes, and often resistant to conventional therapies. Owing to its infrequency, reported clinical characteristics have been diverse and relatively nonspecific. Particularly uncommon is lower extremity involvement, where cutaneous MM is found. Case presentation In this report, we present a unique case of a middle age lady with refractory IgG lambda MM, who subsequently developed recurrent cutaneous plasmacytoma in the lower leg, while being on systemic therapy. Initially, the lesion resembled squamous cell carcinoma, posing a diagnostic challenge. Through meticulous histopathological and immunohistochemical studies, cutaneous involvement by multiple myeloma was conclusively confirmed. Conclusion This case highlights the importance of maintaining a high clinical suspicion for cutaneous MM in patients with MM who present with new skin lesions, as early diagnosis is crucial for appropriate management.